Effectiveness and safety of the ABSORB bioresorbable vascular scaffold for the treatment of coronary artery disease: systematic review and meta-analysis of randomized clinical trials

被引:7
作者
Pavasini, Rita [1 ]
Serenelli, Matteo [1 ]
Gallo, Francesco [1 ]
Bugani, Giulia [1 ]
Geraci, Salvatore [2 ]
Vicinelli, Paolo [3 ]
Campo, Gianluca [1 ,4 ]
机构
[1] Azienda Osped Univ Ferrara, Cardiol Unit, Ferrara, Italy
[2] Osped S Giovanni di Dio, Cardiol Unit, Agrigento, Italy
[3] Osped Fornaroli, Cardiol Unit, ASST Milanese Ovest, Magenta, Italy
[4] Maria Cecilia Hosp, ES Hlth Sci Fdn, GVM Care & Res, Cotignola, Italy
关键词
Bioresorbable vascular scaffold (BVS); absorb; meta-analysis; DRUG-ELUTING STENT; OPTICAL COHERENCE TOMOGRAPHY; METALLIC STENTS; IMPLANTATION; OVERLAP;
D O I
10.21037/jtd.2017.06.59
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: In the last years bioresorbable vascular scaffold (BVS) become a new therapeutic option for interventional cardiologists, with the advantage of a scaffold inducing a possible vessel wall restoration. Nevertheless, several trials tried to prove the safety and efficacy profile of scaffolds, but with conflicting results. Methods: A systematic review and meta-analysis was performed. The search was carried out in PubMed, Google Scholar, Biomed Central and Cochrane Library between January and March 2017. Inclusion criteria: randomized clinical trials (RCT) comparing the Absorb BVS versus durable polymer cobalt-chromium Everolimus Eluting Stent. The outcomes analysed were all-cause mortality, cardiac death, ischemia-driven target lesion revascularization, target vessel myocardial infarction (MI), target lesion failure (TLF)/device oriented composite endpoints (DOCE), and device thrombosis. Fixed-effect meta-analysis was performed. Data were expressed as odds ratio (OR). Results: Overall 5,674 patients were included (mean age 62.2 +/- 1.31 in drug eluting stents (DES) group vs. 62 +/- 1,47 in BVS group; P=0.942). DOCE (OR 1.16, 95% CI: 0.90-1.48; P=0.259, I-2=0%), cardiac death (OR 0.86, 95% CI: 0.52-1.40; P=0.537, I-2=0%) and all-cause death (OR 0.78, 95% CI: 0.53-1.15; P=0.205, I-2=15%) did not differ between BVS and DES. Conversely, ischemia-driven target lesion revascularization was more frequent in the BVS group (OR 1.32, 95% CI: 1.01-1.73; P=0.039, I-2=0%), as well as device thrombosis (2.2% vs. 0.6%, OR 2.94, 95% CI: 1.71-5.05, P=0.0001, I-2=0%) and target-vessel MI (5.4% vs. 3%, OR 1.66, 95% CI: 1.25-2.21, P=0.001, I-2=0%). Conclusions: The implantation of BVS is associated with an increased risk of device thrombosis, ischemiadriven target lesion revascularization and target vessel MI. If longer follow-up or different implantation technique may change these findings should be addressed in future trials.
引用
收藏
页码:S887 / S897
页数:11
相关论文
共 34 条
[31]  
Tamburino C, 2015, EUROINTERVENTION, V11, P45, DOI 10.4244/EIJV11SVA41
[32]   Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction [J].
Togni, M ;
Windecker, S ;
Cocchia, R ;
Wenaweser, P ;
Cook, S ;
Billinger, M ;
Meier, B ;
Hess, OM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 46 (02) :231-236
[33]   Bioresorbable Scaffolds versus Metallic Stents in Routine PCI [J].
Wykrzykowska, Joanna J. ;
Kraak, Robin P. ;
Hofma, Sjoerd H. ;
van der Schaaf, Rene J. ;
Arkenbout, E. Karin ;
Ijsselmuiden, Alexander J. ;
Elias, Joelle ;
van Dongen, Ivo M. ;
Tijssen, Ruben Y. G. ;
Koch, Karel T. ;
Baan, Jan, Jr. ;
Vis, M. Marije ;
de Winter, Robbert J. ;
Piek, Jan J. ;
Tijssen, Jan G. P. ;
Henriques, Jose P. S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (24) :2319-2328
[34]   Bioresorbable scaffolds in the treatment of coronary artery disease [J].
Zhang, Yaojun ;
Bourantas, Christos V. ;
Farooq, Vasim ;
Muramatsu, Takashi ;
Diletti, Roberto ;
Onuma, Yoshinobu ;
Garcia-Garcia, Hector M. ;
Serruys, Patrick W. .
MEDICAL DEVICES-EVIDENCE AND RESEARCH, 2013, 6 (01) :37-48